Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPHNASDAQ:ATXSNASDAQ:BGMNASDAQ:CALT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$25.61-1.4%$24.72$22.64▼$53.96$1.22B0.77489,819 shs399,985 shsATXSAstria Therapeutics$5.70-3.9%$4.69$3.56▼$12.92$322.80M0.39370,093 shs522,470 shsBGMBGM Group$12.65-10.3%$12.21$5.26▼$17.17$1.31B1.3830,846 shs111,926 shsCALTCalliditas Therapeutics AB (publ)$40.00$40.00$15.25▼$43.00$1.19B1.7710,339 shsN/A7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+0.62%-2.40%+4.51%-5.04%-35.84%ATXSAstria Therapeutics+3.67%+2.42%+49.75%-8.63%-35.19%BGMBGM Group+4.44%+6.82%+12.44%+42.71%+1,409,999,900.00%CALTCalliditas Therapeutics AB (publ)0.00%0.00%0.00%0.00%+3.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMPHAmphastar Pharmaceuticals4.155 of 5 stars3.11.00.03.72.24.21.3ATXSAstria Therapeutics2.1819 of 5 stars3.62.00.00.02.81.70.0BGMBGM GroupN/AN/AN/AN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.25Hold$32.3326.25% UpsideATXSAstria Therapeutics 3.25Buy$30.00426.32% UpsideBGMBGM Group 0.00N/AN/AN/ACALTCalliditas Therapeutics AB (publ) 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATXS, BGM, AMPH, and CALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025ATXSAstria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/14/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.005/12/2025AMPHAmphastar PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$45.00 ➝ $30.005/8/2025AMPHAmphastar PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$40.00 ➝ $35.004/29/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$47.004/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/21/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $32.00(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$731.97M1.65$4.96 per share5.16$15.23 per share1.68ATXSAstria TherapeuticsN/AN/AN/AN/A$3.97 per shareN/ABGMBGM Group$25.10M49.00N/AN/A$7.34 per share1.72CALTCalliditas Therapeutics AB (publ)$1.60B0.74N/AN/A$1.06 per share37.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$159.52M$2.769.287.786.7719.38%22.20%10.40%8/6/2025 (Estimated)ATXSAstria Therapeutics-$94.26M-$1.87N/AN/AN/AN/A-47.18%-31.26%8/11/2025 (Estimated)BGMBGM Group-$1.44MN/A0.00∞N/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)-$43.96M-$1.85N/A8.68N/A-30.18%-212.04%-27.96%N/ALatest ATXS, BGM, AMPH, and CALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ATXSAstria Therapeutics-$0.48-$0.58-$0.10-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/AATXSAstria TherapeuticsN/AN/AN/AN/AN/ABGMBGM GroupN/AN/AN/AN/AN/ACALTCalliditas Therapeutics AB (publ)N/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.802.952.02ATXSAstria TherapeuticsN/A17.3917.39BGMBGM GroupN/A3.392.82CALTCalliditas Therapeutics AB (publ)9.442.692.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%ATXSAstria Therapeutics98.98%BGMBGM GroupN/ACALTCalliditas Therapeutics AB (publ)2.83%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals27.10%ATXSAstria Therapeutics4.50%BGMBGM Group58.66%CALTCalliditas Therapeutics AB (publ)2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals2,02847.14 million34.36 millionOptionableATXSAstria Therapeutics3056.43 million53.89 millionOptionableBGMBGM Group29897.22 million40.19 millionN/ACALTCalliditas Therapeutics AB (publ)18029.79 million29.14 millionOptionableATXS, BGM, AMPH, and CALT HeadlinesRecent News About These CompaniesCalliditas hits $90m jackpot as biotech IPO craze continuesFebruary 17, 2025 | pharmaphorum.comCalliditas Therapeutics to Present Four Abstracts at American Society of Nephrology (ASN) Kidney Week 2024October 17, 2024 | tmcnet.comCalliditas Therapeutics (NASDAQ:CALT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comDelisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmSeptember 16, 2024 | prnewswire.comNotice of extraordinary meeting of Calliditas Therapeutics AB (publ)September 3, 2024 | prnewswire.comCalliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiSeptember 3, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comCalliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comCalliditas Therapeutics (spons ADRs) earnings: here's what Wall Street expectsAugust 13, 2024 | markets.businessinsider.comCalliditas Interim Report January to June 2024August 13, 2024 | prnewswire.comLC8.SG,0P0001K80V,0 (LC8.SG)August 12, 2024 | ca.finance.yahoo.comCalliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership ConferenceAugust 1, 2024 | markets.businessinsider.comNumber of shares and votes in Calliditas TherapeuticsJuly 31, 2024 | prnewswire.com(CALT) Trading AdviceJuly 30, 2024 | news.stocktradersdaily.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of ShareholdersJuly 28, 2024 | accesswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger and its Tender Offer for Calliditas Therapeutics AB – CALTJuly 27, 2024 | globenewswire.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring August 30, 2024, for shares of Calliditas Therapeutics AB - CALTJuly 26, 2024 | prnewswire.comCALT Aug 2024 40.000 call (CALT240816C00040000)July 26, 2024 | finance.yahoo.comCalliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitisJuly 26, 2024 | prnewswire.comCalliditas Therapeutics AB (publ) (LC8A.F)July 20, 2024 | nz.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeATXS, BGM, AMPH, and CALT Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$25.61 -0.37 (-1.42%) Closing price 04:00 PM EasternExtended Trading$25.62 +0.00 (+0.02%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Astria Therapeutics NASDAQ:ATXS$5.70 -0.23 (-3.88%) Closing price 04:00 PM EasternExtended Trading$5.58 -0.12 (-2.11%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.BGM Group NASDAQ:BGM$12.65 -1.45 (-10.28%) Closing price 04:00 PM EasternExtended Trading$12.96 +0.32 (+2.49%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Calliditas Therapeutics AB (publ) NASDAQ:CALT$40.00 0.00 (0.00%) As of 06/13/2025Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Analyst Downgrades Joby, But Overlooks Major Regulatory Wins Applied Digital: Now the High-Stakes Race to Build Begins Zscaler Upgraded: Wall Street Forecasts 26% More Upside U.S. Steel Stock Burns the Bears With Surprise Upside Move Is CrowdStrike Stock Set to Break Out or Cool Off? New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 The Bottom Is in for Powerfleet: An Intelligent Time to Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
